Abstract:Mounting evidence indicates that the stimulator of interferon genes (STING) pathway is critical for the effectiveness of standard cancer treatments. However, systemic delivery of STING agonists remains a challenge due to poor tumor-targeting and unwanted toxicities. Here we describe a robust tumor-targeted STING agonist, ZnCDA, formed by the encapsulation of bacterial-derived cyclic dimeric adenosine monophosphate (CDA) in nanoscale coordination polymers. Intravenously injected ZnCDA prolonged CDA circulation and efficiently targeted tumors, mediating robust antitumor effects in a diverse set of preclinical cancer models. Moreover, endothelial STING activation promotes the accumulation of ZnCDA in the tumor tissues by amplifying the enhanced permeability and retention (EPR) effect. In this study, we discover that type I IFN is not required for the antitumor effects of STING agonism by ZnCDA, indicating that differentially formulated STING activators may suppress tumor growth in different ways. Using metal- or dye-labelled nanoparticles, we identified a group of tumor-associated macrophages (TAMs) as the cellular target of ZnCDA in the tumor immune microenvironment. RNA-seq analysis indicated the modulation of TAMs for antigen processing and presentation via STING activation. We further showed that TAMs with ZnCDA uptake promoted an antitumor T cell response. Lastly, we utilized two immunologically “cold” tumor models, a fragment Panc02-SIY pancreatic cancer model and an intracranial GL261 glioma model, both of which represent intractable fatal human cancers, to provide a proof-of-concept strategy for combining ZnCDA with immune checkpoint blockade or radiotherapy in aggressive, difficult-to-treat tumors. a grant from the Ludwig Foundation and an NIH grant (R01CA262508) to R.R.W., NIH grants (R01CA223184 and R01CA216436) to W.L. and NIH grants (R35CA232109 and R01AI141333) to J.P.Y.T. A.P. is the recipient of a Walter Benjamin scholarship provided by the German Research Foundation (Deutsche Forschungsgemeinschaft). J.B. was supported by a Clinical Therapeutics Training Grant (T32GM007019).

Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy

Polymersome Nanoreactor-Mediated Combination Chemodynamic-Immunotherapy via ROS Production and Enhanced STING Activation

Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS–STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy

A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Tumor Microenvironment‐Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy

Single-site Nanozyme with Exposed Unsaturated Cu-O2 Sites for Tumor Therapy by Coordinating Innate Immunity and Vasculature Normalization

An Ultrasound‐Triggered STING Pathway Nanoagonist for Enhanced Chemotherapy‐Induced Immunogenic Cell Death

Multifunctional STING-Activating Mn3 O4 @Au-Dsdna/dox Nanoparticle for Antitumor Immunotherapy.

Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy

Chitosan-based nano-micelles for potential anti-tumor immunotherapy: Synergistic effect of cGAS-STING signaling pathway activation and tumor antigen absorption

STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition

Zinc-c-di-AMP nanoparticles target and suppress tumors via endothelial STING activation and tumor associated macrophage reinvigoration

A magnetic resonance nanoprobe with STING activation character collaborates with platinum-based drug for enhanced tumor immunochemotherapy

Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway